Racial Differences in Trust and Regular Source of Patient Care, and Implications for Prostate Cancer Screening Utilization by Carpenter, William R. et al.
Racial Differences in Trust and Regular Source of Patient Care,
and Implications for Prostate Cancer Screening Utilization
William R. Carpenter, PhD1,2,3,4, Paul A. Godley, MD, PhD2,3,5,6, Jack A. Clark, PhD7, James
A. Talcott, MD8, Timothy Finnegan, MD5, Merle Mishel, PhD9, Jeannette Bensen, PhD2,6,
Walter Rayford, MD10, L. Joseph Su, PhD11, Elizabeth T.H. Fontham, PhD11, and James L.
Mohler, MD2,12,13
1University of North Carolina (UNC) School of Public Health, Department of Health Policy &
Management, Chapel Hill, NC
2UNC-Lineberger Comprehensive Cancer Center
3UNC Cecil G. Sheps Center for Health Services Research
4North Carolina Comprehensive Cancer Program, Raleigh, NC
5UNC School of Medicine, Department of Medicine
6UNC School of Public Health, Department of Epidemiology
7Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial
Veterans Hospital, Bedford, MA and Boston University School of Public Health, Boston, MA
8Center for Outcomes Research, Massachusetts General Hospital Cancer Center and Harvard
Medical School, Boston, MA
9UNC School of Nursing
10University of Tennessee School of Medicine, Department of Preventive Medicine, Memphis, TN
11Louisiana State University Health Science Center, New Orleans, LA
12Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY
13Department of Urology, University at Buffalo, State University of New York, Buffalo, NY
Abstract
Background—Nonmedical factors may modify biological risk of prostate cancer and contribute
to differential use of early detection, curative care, and ultimately greater racial disparities in
prostate cancer (CaP) mortality. This study examines patients' usual source of care, continuity of
care, and mistrust of physicians and their association with racial differences in CaP screening.
Methods—Study nurses conducted in-home interviews of 1,031 African American and
Caucasian American men age 50 and over in North Carolina and Louisiana within weeks of their
CaP diagnosis. Medical records were abstracted. Bivariate and multivariate analyses were
conducted.
Results—Compared with African Americans, Caucasian Americans exhibited higher physician
trust scores and a greater likelihood of reporting a physician office as their usual source of care,
seeing the same physician at regular medical encounters, and historically utilizing any CaP
screening. Seeing the same physician for regular care was associated with greater trust and
screening utilization. Men who reported their usual source of care as a physician office, hospital
clinic, or Veteran's Affairs facility were more likely to report prior CaP screening than other men.
In multivariate regression, seeing the same provider remained associated with prior screening use
while both race and trust lost their association with prior screening.
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Conclusions—Systems factors – including those that differ among different sources of care and
those associated with care continuity – may provide tangible targets to address disparities in the
use of CaP early detection, attenuate racial differences in CaP screening utilization, and contribute
to reduced racial disparities in CaP mortality.
Introduction
Prostate cancer (CaP) presents one of the greatest cancer burdens for men, with the highest
incidence and second highest number of deaths from cancer among men in the United
States1. The CaP incidence rate among African Americans (AAs) is 55% greater than
among Caucasian Americans (CAs), and the AA mortality rate is an astounding two and a
half times that of CAs 1. Genetic and dietary factors have been identified that explain a
portion of the excess burden experienced by AAs 2–5, yet risk factors that are both of
substantial magnitude and amenable to preventive intervention have not yet been identified
6.
In addition to biological risk factors, a variety of other factors including mistrust of
physicians, lack of a usual source of care, and lack of continuity of care have been
associated with reduced use of preventive and curative services, delayed care, and disparities
in cancer and other health outcomes 7–12. AA patients report lower levels of trust in
healthcare providers than CA patients, and both personal health care experiences and past
discrimination have been implicated 13–16. Racial discrimination has been shown to reduce
continuity of care and increase mistrust of providers 14, 15, 17–19, which may reduce AAs'
use of recommended treatments, hinder the provision or acceptance of physician advice to
undergo screening, or reduce discussion of the risks and benefits of CaP screening and early
detection20–24. AAs' lower trust, lower likelihood of having any regularsource of care or
using private physician offices for regular care, and lower likelihood of having an ongoing
relationship with the same provider may contribute to delayed diagnosis and greater disease
severity among AAs 25–32. While CaP screening remains controversial, these three factors
– mistrust, regular source of care, and continuity of care – are potential points of
intervention, and therefore merit examination to enhance our understanding of racial
differences in prostate cancer screening and outcomes.
Grounded in a framework described by the IOM7, this study examined the association
between mistrust of physicians, patients' usual source of care, continuity of care and
differential use of CaP screening in a large cohort of CA and AA men with recently
diagnosed prostate cancer. Previous work proposed that AAs without a regular source of
care may be less likely to know their providers well enough to develop trust, thus reducing
the likelihood of discussing and subsequently receiving CaP screening 33. This work
broadens the examination to include systems and process factors that may be associated with
both CaP screening and trust, to inform our understanding of contributors to racial
disparities in CaP outcomes, and improve public health and policy interventions to reduce
them.
Methods
Patient Population and Sample
Methodology of the North Carolina-Louisiana Prostate Cancer Project (PCaP) was described
in detail previously 33. Briefly, PCaP is a population-based study of individuals identified
shortly after CaP diagnosis. Study enrollment began in both states in September 2004. The
original intent was to contemporaneously enroll equally from each state; however, study
enrollment was stopped in Louisiana due to Hurricane Katrina (it resumed 2 years later).
Hurricane Katrina substantially disrupted the health care systems, practices of providers that
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interfaced with the prospective study population, as well as the local population itself,
causing substantial differences between the pre- and post-Katrina populations. As such,
Post-Katrina Louisiana participants were not included in this analysis. The extent and
implications of this disruption are under ongoing examination, and individuals enrolled after
Katrina will be carefully included in future analyses.
Eligible individuals were identified in North Carolina through the Rapid Case Ascertainment
Core Facility, a collaborative program of the UNC-Lineberger Comprehensive Cancer
Registry and the North Carolina Central Cancer Registry, and in Louisiana through the
Louisiana Tumor Registry in the Louisiana State University Health Science Center School
of Public Health. Both programs allow case ascertainment and enrollment that is much faster
and more complete than most traditional registries. Prospective participants were typically
identified within weeks of their diagnosis, and following randomization, physician
notification, and study participants were enrolled. An appointment was scheduled with a
study nurse (in-home or at a location of their choosing) to collect obtain consent and
biospecimens, and conduct a 749 question structured survey. The visits averaged slightly
more than three hours, including two breaks.
Since organizations offering screening recommendations generally recommend screening
begin at age 5034, the analytic sample was limited to men ages 50 and older (maximum age
was 79). Our analytic sample size was 1,031 men (503 AA, 528 CA), including those from
North Carolinia (NC) for whom enrollment, interviews, and primary data collection were
complete through May 2007, and those from Louisiana (LA) who enrolled prior to
Hurricane Katrina (August 29, 2005).
Analytic Framework
The IOM provides a framework for examining contributors to health disparities. In addition
to patient-level factors, the IOM describes healthcare systems factors, process factors, and
the dynamic interplay of patient and provider attitudes and behaviors 7, 8, 35. Systems
factors include availability of health care facilities, the services offered at those facilities, the
systems in place to trigger appropriate utilization of those services, and clinician time
pressures or encounter characteristics that may impede their ability to fully address patient
needs 7. Process factors include provider bias, erroneous stereotypes, or lack of
understanding of minorities, all of which can contribute to decision-making based on
incomplete or inaccurate information. All of these factors may influence patient trust, health
behaviors, and receptivity toward seeking or utilizing particular health care services7,
including CaP screening.
Measures
Two outcome variables – trust, and pre-diagnostic CaP screening utilization – were
examined using sequential analytic models. Trust is a 100-point index measure of patient-
physician trust based on a 12-item patient survey instrument adapted from the Safran36 and
LaVeist17 instruments. Factor analysis of the Trust instrument demonstrated good internal
consistency (0.77) and loaded on two factors, one characterized as “concern with doctors
hiding mistakes and bias in care delivery,” and the other with “a theme of candor,
disclosure, and personal concern.” Pre-diagnostic CaP screening is a binary measure that
summarizes patient reported pre-diagnosis Prostate-Specific Antigen (PSA) and digital
rectal exam (DRE) screening. Men reporting use of either pre-diagnostic PSA, DRE, or both
prior to the interaction that led to the diagnosis of CaP were coded as having had CaP
screening. This “either-or-both” measure was used for two reasons: (1) PSA and DRE are
both prescribed by the groups that offer guidelines regarding prostate cancer screening and
early detection, and (2) excluding either PSA or DRE may bias associations of interest
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because use of PSA and DRE for screening/early detection differs by race. Trust is
examined as the dependent variable in model 1, and as an independent variable in model 2.
Two independent variables capture systems factors. Seeing the same care provider at each
visit, a measure of pre-diagnosis care patterns and continuity of care, was based on the
survey question, “Did you see a particular doctor, nurse or other medical person [at your
usual source of care], or did you see a different person at each visit?” Similarly, patient's
usual source of care was examined based on the eight response-item interview question,
“Before you were diagnosed with prostate cancer, what kind of place did you usually go to
when you had a medical problem?”
Several patient health, social, and economic characteristics that have been associated
previously with care-seeking behaviors, support for care-seeking, and access to care were
examined (Table 1). The Charlson Index of historical health issues was constructed from a
comorbidity questionnaire37, 38. Using the SF-12 Health Survey, version 2 39, current
physical and mental health and well-being were characterized that may influence current
perceptions and survey response. The REALM questionnaire was used to assess health
literacy 40, 41. Patient-physician communication was assessed using a five-item instrument
and, along with the trust measure, describe process and patient-provider interaction
characteristics. A binary measure of state of residence (NC or LA) was included to control
for systematic differences by state.
Analysis
T-tests, Fisher's Exact tests, and Chi-squared tests were used to test differences in mean
values and categorical distributions of multi-category binary variables, as appropriate. The
primary analysis consisted of three stages. First, linear regression was used to analyze the
association between covariates and the dependent variable trust. Second, logistic regression
was used to analyze the association between covariates, including trust, and the dependent
variable, CaP screening use. White tests indicating the presence of heteroskedasticity
prompted the use of robust standard errors (Huber/White/sandwich estimator of variance) in
both models 42. Finally, differences in a history of prior screening in association with
continuity of care and usual source of care (caresite) were examined independently through
binomial linear regression models with and without adjustment or stratification by race.
Proper functional form of variables in the analytic models was examined, and continuous
variables with non-normal distributions or non-linear association with the dependent
variables were reshaped into multi-category binary variables or were coupled with their
quadratic term. Results of Wooldridge tests43 of functional form of the trust variable
indicated that deviating from the natural form was not perceived to add value; accordingly,
the variable was used in its natural form. Multi-category response measures (e.g., income,
education, health literacy, marital status, type of health insurance) were examined with
regard to explanatory power, magnitude, and direction of covariate associations, and
subsequently collapsed into fewer categories to preserve degrees of freedom and statistical
power in the analytic models. Health insurance was examined independently and in
combination with age to assess differences among different types of insurance and structural
differences between those younger than age 65 and those 65 and over who may be eligible
for Medicare. Deviating from a binary measure (any insurance vs. no insurance) did not
improve overall model fit.
Results
CAs had higher physician trust scores than AAs (62.7 vs. 58.5) and greater past use of CaP
screening of any kind (93.9% vs. 81.4%) (Table 1). Most participants saw the same provider
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at each medical encounter, though CAs did so more often than AAs (89.4% vs. 78.5%) and
CAs were more likely than AAs to report a physician office or group practice as their usual
source of care (88.5 % vs. 65.9%). At diagnosis, CAs were older, wealthier, more likely to
have ever been married, and more likely to have health insurance. Respondents were well
educated, with most having completed or gone beyond high school, though CAs had
received more formal education, had higher REALM health literacy scores, and reported
better physician communication than AAs. AAs had lower current physical, mental health
and global well-being scores than CAs, but the measured differences were small, and
comorbidity and family history of CaP were similar. Stage at diagnosis was similar between
races, but mean Gleason scores were slightly higher for AAs than CAs. The link between
screening and tumor characteristics was not extensively examined; however, men reporting
a prior history of screening were more likely than other men to be diagnosed with local or
regional stage CaP (98.5% vs. 94.3% stage I or II, p<.01), and lower grade CaP (88.3% vs.
81.6% with Gleason score less than 8, p<.05). Participants were similar between states, with
moderate differences among a few measures. In bivariate analysis, North Carolina
participants reported higher income and were more likely to have insurance (88.6% vs.
82.1%), more formal education (56.8% vs. 39.1% education level greater than high school
graduate), and a history of CaP screening (89.7% vs. 80.9%). At the same time, North
Carolina participants had slightly, though statistically significantly, lower scores than did
Louisiana participants for communication (86.9 vs 89.6), health literacy (.71 vs. 1.0), and
trust (60.2 vs. 62.9).
In regression analysis, overall, mean levels of trust varied in association with patient
characteristics; however, differences in mean scores were small. Relative to other covariates,
differences in trust by race were larger, with AAs expressing lower trust than CAs (Table 2).
Communication and greater self-reported mental health and well-being had a positive
association with trust (an 2.3 unit increase in trust with every 10 unit increase in
communication), while men who were high school graduates or beyond expressed lower
trust than less educated men (−1.90), as did men from North Carolina relative to men from
Louisiana (−2.53).
Results of the logistic regression of prior CaP screening on trust and covariates (Table 2)
suggest that trust was not directly associated with CaP screening; however, seeing the same
provider (OR 2.40, 95% CI 1.47–3.92), having ever been married (OR 2.49, 95% CI 1.14–
5.46), and having any form of health insurance (OR 1.97, 95% CI 1.17–3.34) were all
associated with prior CaP screening. Low income (vs. high income, OR 0.24, 95% CI 0.12–
0.47) was negatively associated with screening, while men with a high school or higher level
of education were more than twice as likely to report screening as less educated men (OR
2.26, 95% CI 1.25–4.11), as were men with a health literacy score above sixth grade
(relative to men with lower health literacy scores, OR 2.12, 95% CI 1.26–3.55).
When examining trust, consistency of provider, and usual source of care (Table 3), mean
trust was slightly greater in men who saw the same provider at each visit relative to men
who did not (mean trust score of 61.04 vs. 58.75). In both circumstances, CAs had slightly
higher mean trust scores than AAs (saw same provider: 60.96 vs. 57.58; did not see same
provider: 62.94 vs. 58.72 for CAs and AAs, respectively). Mean trust scores were lower for
men who reported an ER, UCC, or “none” as their regular care site (57.90), and for men
who used the VA (58.87), than for men whose usual care site was a physician practice
(60.91), hospital clinic (62.17), or a public health / community clinic (61.90). Differences in
mean trust scores according to the source of usual care were comparable between CAs and
AAs.
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Men who usually saw the same provider reported greater use of CaP screening compared
with men who did not usually see the same provider, both overall (91.0% vs. 71.0%,
prevalence difference (PD) −20.0, 95% CI −27.3, −12.8), and by race (PD −19.1, CI −30.3,
−7.9 among CAs; PD −17.2, CI −26.7, −7.6 among AAs), with no statistically significant
difference in the association between seeing the same provider and CaP screening according
to race (Table 4). Prior CaP screening use was more likely among men whose regular source
of care was one of 3 sites – a physician office, hospital clinic, or the VA health system
(90.9%, CI 89.0, 92.7) – compared with men who received care at Public Health or
Community Clinics, an Emergency Room or urgent care center, or reported no usual source
of care (51.9%, CI 40.8, 63.1). Among CAs, 95% of men at the 3 sites reported having had
CaP screening, compared with 63% at the other sites, a relative difference of 34% (PR 0.66,
CI 0.48, 0.89). The relative difference was somewhat larger among AA men, with 86%
reporting having had CaP screening at the 3 sites, compared with 47% at the other sites, a
relative difference of 45% (PR 0.55, CI 0.41, 0.73). The difference between 34% for CAs
and 45% for AAs was not statistically significant for this study population (MH chi2 p-value
0.41).
Discussion
To better understand racial disparities in CaP mortality, we examined relationships between
CaP patients' trust in their physicians, continuity of health care, regular source of health care,
and their utilization of CaP screening. In our study population of newly-diagnosed prostate
cancer patients, AAs were less likely than CAs to report CaP screening prior to diagnosis,
and men without a prior history of screening were more likely to be diagnosed with
advanced stage or high grade CaP than men who reported a history of CaP screening. While
the efficacy of PSA screening remains controversial34, these findings support the hypothesis
that addressing differences in screening use may reduce racial disparities in CaP extent of
disease and aggressiveness at diagnosis, and, by extension, that addressing differences in
screening may reduce disparities in CaP mortality 44. Adjusting for patient-provider
interaction, health systems, and processes sharply attenuated the association between race
and CaP screening history in multivariate analysis. Previously, we reported an association
between having a consistent care provider and trust in health care providers 45; in this study
of CaP patients, seeing a regular provider was more closely associated with prior utilization
of CaP screening, while trust showed no association with screening in multivariable
analysis.
This analysis examined men already diagnosed with CaP, whose prerequisite access to the
health care system may have required some baseline level of trust in their physicians and the
health care community. This study found that, upon passing this threshold, however, other
system variables including setting and continuity of care predict use of screening. Study
results thus reframe the question: To what degree are lower trust and lesser use of screening
a function of individual patient and physician characteristics versus systems factors that may
hinder trust and relationship development?
Physician biases or practical constraints may inhibit their ability to inquire beyond the
primary clinical issue at hand to secondary problems, preventive and health maintenance
issues, or other more complex medical decisions. An ongoing patient-provider relationship
may enable the relationship to grow past the tipping point of sufficient strength to discuss
these issues and overcome barriers to screening use such as fear of the exam itself,
prospective diagnosis, or potential treatment side-effects 8. On a more practical level, such a
relationship may simply expedite provider-patient interaction, allowing additional time and
resources to address more complex issues over time, including decisions regarding use of
preventive care such as cancer screening or, as described by other studies, vaccinations 24.
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Discussions about screening and early detection also may be promoted by office and support
systems. For example, patient records may provide reminders of prior visits, other clinical
conditions, and include prompts for patient-appropriate services. Differences in use of CaP
screening have been reported by regular source of care. For example, prior research has
demonstrated the weaknesses of emergency departments and urgent care centers for
provision of preventive care 27–30. Simultaneous analysis of regular source of care and
seeing the same provider suggests that seeing the same provider may partially overcome
observed differences between public and community health clinics, private practice, hospital
clinics, and VA facilities to foster use of preventive care. Men who reported not seeing the
same provider also reported less CaP screening use; however, data limitations impeded a
precise demonstration of the relationships among the caresites.
These findings suggest the need for additional research examining the roles of provider
continuity and the systems in place at the usual source of care, possibly directed toward an
intervention targeting health care organizations. The limitations of this study suggest
additional avenues as well. Having health insurance improves utilization of both early
detection and treatment-oriented health services 35. Characterizing pre-diagnosis insurance
beyond our indicators “any insurance” and “no insurance” may clarify the expected
association between having insurance and use of PSA/DRE prior to diagnosis found in this
study. Differences in insurance between NC and LA and changes in men's insurance after
diagnosis also merit examination. Insurance coverage is relevant for several reasons,
including that it may influence the reporting of DRE compared with PSA, which may be
directly related to the type, timing, and duration of insurance coverage. The reported use of
PSA (which is separately billable) may be low compared to DRE (which is included in
comprehensive physical examinations) because PSA is less commonly used in the absence
of consistent financial resources. PSA use may also be underreported because a PSA test can
be added to a panel of other blood tests without the patient knowing it, whereas DRE rarely
goes unnoticed, though it could conceivably be confused with examinations for other
conditions. For researchers examining CaP screening, insurance claims and medical records
may be used to augment these self-reported data, but insurance claims only capture PSA
testing for the insured, comprehensive gathering of medical records is expensive, and
documentation of non-billable procedures like DRE is often spotty.
Like our measures of insurance status, our measure of trust could be enhanced. Trust was
assessed at a single point in time (post-diagnosis) and analyzed in the context of antecedent
health behavior (pre-diagnostic screening use). Trust measured at this point may be different
and less relevant than trust before diagnosis, or earlier, when men's health care behaviors
may have formed. These findings generally support the conclusions of previous research
showing that patients who have familiarity, better communication, and longer relationships
or more visits with their physicians report comparatively greater trust 15, 46–50. Moreover,
the data encourage more nuanced characterization of both race and trust than as monolithic,
homogeneous, and invariant. Instead, AA men, like CAs, are both socially vulnerable and
heterogeneous, and the trust they exhibit is a dynamic function of multiple characteristics
that may vary over time and by context.
The attenuation of racial differences in screening use seen in the multivariable model
suggests that approaching the problem from multiple angles holds merit; however, the
persistence of disparities in all strata of trust and structure of usual care reinforces the
complexity of the problem. Adapting systems to assure provider continuity may facilitate
patient-provider interactions that extend beyond the primary problem at hand. Adoption of
additional systems to prompt and facilitate preventive care may provide additional benefit,
especially among public health and community clinics, and even ERs and UCCs that
acknowledge and accept that they are some people's primary care providers 51, 52. The
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means of enhancing trust among the broader population remains unclear, although this study
suggests that addressing systems issues may be an important route of intervention to
improve trust among those who access health care services. Doing so may contribute to trust
and attenuate racial differences in the short term, which may in turn feed back into the
community and contribute to a resolution of differences in trust, access, and outcomes in the
long term for the broader population.
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Table 2
Linear Regression (Model 1): Association of Covariates with Patient-Reported Trust of Physician; and
Logistic Regression (Model 2): Association of Covariates with Pre-Diagnostic CaP Screening Use.
Model 1: Regression, Trust on Covariates Model 2: Logit, PCa Screening on Trust and Covariates
Coef. P Value OR [95% CI]
Trust (Dependent variable this model) 1.000 [0.979 – 1.021]
Sees Same Clinician 1.738 0.100 2.397 [1.468 – 3.916]
African American Race −3.540 <0.001 1.011 [0.579 – 1.766]
Communication 0.229 <0.001 1.011 [0.997 – 1.025]
Ever Married 0.521 0.705 2.494 [1.140 – 5.459]
Age 0.028 0.613 1.015 [0.977 – 1.056]
Income: <$29k −0.221 0.834 0.238 [0.122 – 0.465]
Income: $30 - $59k −1.508 0.093 0.972 [0.411 – 2.295]
Income: $60k+ (Reference) (Reference)
Insurance 0.664 0.582 1.972 [1.165 – 3.338]
Fam History of Pca 0.055 0.949 1.330 [0.736 – 2.404]
Education > HS Grad −1.902 0.021 2.264 [1.249 – 4.105]
Health Literacy: > 6th Grade −0.139 0.890 2.116 [1.263 – 3.545]
SF-12: Physical 0.053 0.112 0.998 [0.977 – 1.018]
SF-12: Mental 0.107 0.003 1.012 [0.991 – 1.033]
Charlson=0 0.262 0.772 0.617 [0.338 – 1.128]
Charlson=1 0.407 0.695 0.606 [0.309 – 1.189]
Charlson>1 (Reference) (Reference)
State of Residence is NC −2.525 0.005 1.389 [0.829 – 2.328]
_cons 33.645 <0.001 - - -
Number of observations 979 967
F(16,962) / WaldChi2(18) 10.80 126.42
Prob > F / Prob > Chi-squared 0.0000 0.0000
R-squared / Pseudo R-Squared 0.1509 0.2633






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cancer. Author manuscript; available in PMC 2010 November 1.
